EMG
SYRS

ETF Managers Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ETF Managers Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,227
Closed -$161K – 803
2021
Q1 		$161K Sell
2,227
-718
-24% -$74.6K ﹤0.01% 623
2020
Q4 		$350K Sell
2,945
-858
-23% -$78.3K 0.01% 517
2020
Q3 		$364K Buy
+3,803
New +$432K 0.01% 382

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

ETF Managers Group's SYRS Position: Q2 2021 in Review

ETF Managers Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 2,227 shares — an estimated $161K sold.

ETF Managers Group first reported a position in SYRS in Q3 2020 and held it in 3 quarters. The position peaked at $364K in Q3 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • ETF Managers Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 2,227 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $161K.
  • ETF Managers Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • ETF Managers Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $364K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.